SCHEMBL21178491

SCHEMBL21178491

COc1cc(C(=N)NO)cc2c1[C@H](NC(=O)OC(C)(C)C)CC2

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 4/20 0.38
▸ PDE4A P27815 1/20 0.38
▸ PDE4C Q08493 1/20 0.38
▸ PDE4D Q08499 1/20 0.38
▸ GAA P10253 1/20 0.34
▸ KDM4D Q6B0I6 2/20 0.34
▸ TAS1R3 Q7RTX0 1/20 0.34
▸ TAS1R1 Q7RTX1 1/20 0.34
▸ NPY1R P25929 1/20 0.34
▸ BDKRB1 P46663 1/20 0.33
▸ SCN9A Q15858 2/20 0.33
▸ SUV39H2 Q9H5I1 1/20 0.33
▸ HDAC8 Q9BY41 1/20 0.33
▸ KDM1A O60341 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ NFKB1 P19838 1/20 0.33
▸ NFKB2 Q00653 1/20 0.33
▸ RELA Q04206 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21178715 0.83 PDE4B (0.41) PDE4BPDE4APDE4CPDE4DGAA
SCHEMBL21284839 0.82 PDE4B (0.40) PDE4BPDE4APDE4CPDE4DGAA
SCHEMBL19961243 0.81 PDE4B (0.41) PDE4BPDE4APDE4CPDE4DGAA
SCHEMBL21178383 0.79 CA12 (0.40) PDE4BPDE4APDE4CPDE4DGAA
SCHEMBL21178718 0.78 DRD2 (0.43) PDE4BPDE4APDE4CPDE4DGAA
SCHEMBL21178689 0.73 KMT2A (0.41) TAS1R3TAS1R1
SCHEMBL21178362 0.72 HTT (0.42) BDKRB1
SCHEMBL18854494 0.72 CA1 (0.43) PDE4BPDE4APDE4CPDE4DTAS1R3
SCHEMBL29134358 0.72 PDE4A (0.39) PDE4BPDE4APDE4CPDE4DTAS1R3
SCHEMBL30015936 0.72 PDE4A (0.39) PDE4BPDE4APDE4CPDE4DTAS1R3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059173-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2025-02-20 — — US disclosed
EP-4491622-A2 CARDIAC SARCOMERE INHIBITORS Cytokinetics, Inc. (US) 2025-01-15 — — EP disclosed
EP-3740481-B9 DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2024-10-23 — — EP disclosed
US-12065436-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2024-08-20 — — US disclosed
EP-3740481-B1 DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2024-06-26 — — EP disclosed
CN-117964573-A Dihydrobenzofuran and indene analogs as myocardial segment inhibitors 赛特凯恩蒂克公司 2024-05-03 — — CN disclosed
CN-117924208-A Dihydrobenzofuran and indene analogs as myocardial segment inhibitors 赛特凯恩蒂克公司 2024-04-26 — — CN disclosed
CN-111757875-B Dihydrobenzofuran and indene analogs as myocardial segment inhibitors 赛特凯恩蒂克公司 2024-01-09 — — CN disclosed
US-20230119665-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2023-04-20 — — US disclosed
US-11472796-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2022-10-18 — — US disclosed
US-20210147399-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2021-05-20 — — US disclosed
EP-3740481-A1 DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS Cytokinetics, Inc. (US) 2020-11-25 — — EP disclosed
US-10836755-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2020-11-17 — — US disclosed
CN-111757875-A Dihydrobenzofuran and indene analogs as inotropic agents 赛特凯恩蒂克公司 2020-10-09 — — CN disclosed
US-20190256504-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2019-08-22 — — US disclosed
WO-2019144041-A1 DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. (US) 2019-07-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230119665-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 PDE4B 709/4885PDE4A 790/4885PDE4C 1221/4885
US-10836755-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 PDE4B 709/4885PDE4A 790/4885PDE4C 1221/4885
US-20210147399-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 PDE4B 709/4885PDE4A 790/4885PDE4C 1221/4885
US-12065436-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 PDE4B 709/4885PDE4A 790/4885PDE4C 1221/4885
US-11472796-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 PDE4B 709/4885PDE4A 790/4885PDE4C 1221/4885
US-20190256504-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 PDE4B 709/4885PDE4A 790/4885PDE4C 1221/4885
US-20250059173-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 PDE4B 709/4885PDE4A 790/4885PDE4C 1221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback